SC13: Design Strategies and Development of ADCs
thursday, may 7 | dinner, 5:45 - 8:15pm
ABOUT THIS COURSE:
Recent innovations in ADC technologies provide new opportunities for successful drug development. What are the critical design factors? What are the considerations for successful ADC development? This short course will review ADC design concepts and strategies for ADC development, including biomarker and patient selection strategies.
COURSE AGENDA:
- Review of the recent innovations for ADC components: binders, bioconjugation, linkers and payloads
- Assessment of ADC design goals
- Review of ADC development goals
- Biomarker strategies – patient selection
- Q&A
WHO SHOULD ATTEND:
This course is appropriate for ADC researchers and development team members interested in ADC design and development, including research associates, scientists, business development managers, project managers, etc.
INSTRUCTOR BIOGRAPHY:
Robert Lutz, PhD, CSO, Iksuda Therapeutics
With more than 25 years’ experience, Bob was previously VP of Translational Research and Development at ImmunoGen Inc., where he was responsible for all early-stage ADC development programs and gained further experience in directing the clinical
pharmacology, biomarkers, pharmacology and toxicology departments. While at ImmunoGen, Bob was responsible for bringing eight of ImmunoGen’s candidate ADC products into development and was the research lead for Kadcyla®.